AU1253892A - Measles virus recombinant poxvirus vaccine - Google Patents
Measles virus recombinant poxvirus vaccineInfo
- Publication number
- AU1253892A AU1253892A AU12538/92A AU1253892A AU1253892A AU 1253892 A AU1253892 A AU 1253892A AU 12538/92 A AU12538/92 A AU 12538/92A AU 1253892 A AU1253892 A AU 1253892A AU 1253892 A AU1253892 A AU 1253892A
- Authority
- AU
- Australia
- Prior art keywords
- virus
- plasmid
- dna
- recombinant
- vaccinia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000712079 Measles morbillivirus Species 0.000 title claims description 109
- 229940024231 poxvirus vaccine Drugs 0.000 title description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 75
- 241000700605 Viruses Species 0.000 claims description 54
- 108020004414 DNA Proteins 0.000 claims description 50
- 241001465754 Metazoa Species 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 36
- 230000004927 fusion Effects 0.000 claims description 33
- 229960005486 vaccine Drugs 0.000 claims description 33
- 108090000288 Glycoproteins Proteins 0.000 claims description 31
- 102000003886 Glycoproteins Human genes 0.000 claims description 31
- 230000006798 recombination Effects 0.000 claims description 31
- 238000005215 recombination Methods 0.000 claims description 28
- 241000178270 Canarypox virus Species 0.000 claims description 24
- 241000712045 Morbillivirus Species 0.000 claims description 20
- 230000028993 immune response Effects 0.000 claims description 9
- 241000700663 Avipoxvirus Species 0.000 claims description 7
- 101900237959 Measles virus Hemagglutinin glycoprotein Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000000655 Distemper Diseases 0.000 claims description 5
- 208000014058 canine distemper Diseases 0.000 claims description 4
- 101710121925 Hemagglutinin glycoprotein Proteins 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 description 141
- 239000012634 fragment Substances 0.000 description 76
- 206010046865 Vaccinia virus infection Diseases 0.000 description 75
- 208000007089 vaccinia Diseases 0.000 description 75
- 101710154606 Hemagglutinin Proteins 0.000 description 61
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 61
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 61
- 101710176177 Protein A56 Proteins 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 58
- 108090000623 proteins and genes Proteins 0.000 description 56
- 241000282472 Canis lupus familiaris Species 0.000 description 49
- 238000012217 deletion Methods 0.000 description 46
- 230000037430 deletion Effects 0.000 description 46
- 238000011081 inoculation Methods 0.000 description 45
- 239000000185 hemagglutinin Substances 0.000 description 43
- 241000712083 Canine morbillivirus Species 0.000 description 39
- 201000005505 Measles Diseases 0.000 description 38
- 239000013598 vector Substances 0.000 description 32
- 108091034117 Oligonucleotide Proteins 0.000 description 30
- 241000283973 Oryctolagus cuniculus Species 0.000 description 29
- 101150039660 HA gene Proteins 0.000 description 28
- 238000010276 construction Methods 0.000 description 27
- 230000003472 neutralizing effect Effects 0.000 description 27
- 241000588724 Escherichia coli Species 0.000 description 24
- 108010005774 beta-Galactosidase Proteins 0.000 description 24
- 210000003501 vero cell Anatomy 0.000 description 22
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 19
- 230000001681 protective effect Effects 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 19
- 102000005936 beta-Galactosidase Human genes 0.000 description 18
- 230000029087 digestion Effects 0.000 description 17
- 238000001114 immunoprecipitation Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 108010017826 DNA Polymerase I Proteins 0.000 description 16
- 102000004594 DNA Polymerase I Human genes 0.000 description 16
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 16
- 238000003780 insertion Methods 0.000 description 16
- 230000037431 insertion Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 230000000405 serological effect Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 230000002238 attenuated effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 241000700198 Cavia Species 0.000 description 13
- 230000003053 immunization Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 101150060895 I4L gene Proteins 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 11
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 10
- 108700026244 Open Reading Frames Proteins 0.000 description 10
- 101150039990 B13R gene Proteins 0.000 description 9
- 101150034814 F gene Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 101150071286 SPI-2 gene Proteins 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 9
- 238000012809 post-inoculation Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 230000007910 cell fusion Effects 0.000 description 8
- 239000013553 cell monolayer Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- 231100000350 mutagenesis Toxicity 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- 230000003141 anti-fusion Effects 0.000 description 6
- 230000002008 hemorrhagic effect Effects 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 108020004440 Thymidine kinase Proteins 0.000 description 5
- 101100534084 Vaccinia virus (strain Copenhagen) B14R gene Proteins 0.000 description 5
- 101100004092 Vaccinia virus (strain Western Reserve) VACWR196 gene Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 101710112753 A-type inclusion protein A25 homolog Proteins 0.000 description 4
- 206010037742 Rabies Diseases 0.000 description 4
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 4
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 4
- 101150003725 TK gene Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 238000009589 serological test Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 241000700662 Fowlpox virus Species 0.000 description 3
- 208000004068 Morbillivirus Infections Diseases 0.000 description 3
- 241000282695 Saimiri Species 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 208000000666 Fowlpox Diseases 0.000 description 2
- 101150082239 G gene Proteins 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- 101100277251 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HEM12 gene Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940124590 live attenuated vaccine Drugs 0.000 description 2
- 229940023012 live-attenuated vaccine Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 231100001023 lymphopenia Toxicity 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000012808 pre-inoculation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012770 revaccination Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 238000006677 Appel reaction Methods 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000701101 Canine adenovirus 1 Species 0.000 description 1
- 241000701114 Canine adenovirus 2 Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 238000012218 Kunkel's method Methods 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 241000634212 Penia Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241001147385 Potos flavus Species 0.000 description 1
- 241000282696 Saimiri sciureus Species 0.000 description 1
- 241000287231 Serinus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 241000700622 Vaccinia virus Copenhagen Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 101150061325 mv gene Proteins 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 101150069452 z gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU60513/96A AU699903B2 (en) | 1990-11-20 | 1996-07-15 | Measles virus recombinant poxvirus vaccine |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62161490A | 1990-11-20 | 1990-11-20 | |
| US621614 | 1990-11-20 | ||
| US77686791A | 1991-10-22 | 1991-10-22 | |
| US776867 | 1991-10-22 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU60513/96A Division AU699903B2 (en) | 1990-11-20 | 1996-07-15 | Measles virus recombinant poxvirus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1253892A true AU1253892A (en) | 1992-06-11 |
Family
ID=27089007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU12538/92A Abandoned AU1253892A (en) | 1990-11-20 | 1991-11-20 | Measles virus recombinant poxvirus vaccine |
Country Status (12)
| Country | Link |
|---|---|
| JP (2) | JP3617668B2 (enExample) |
| AU (1) | AU1253892A (enExample) |
| BE (1) | BE1005908A5 (enExample) |
| CA (1) | CA2096633A1 (enExample) |
| CH (1) | CH683921A5 (enExample) |
| DE (2) | DE4192786T1 (enExample) |
| FR (1) | FR2669346B1 (enExample) |
| GB (2) | GB2264949B (enExample) |
| IE (2) | IE68404B1 (enExample) |
| IT (1) | IT1252687B (enExample) |
| NL (2) | NL195058C (enExample) |
| WO (1) | WO1992008789A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU672359B2 (en) * | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| AU672581B2 (en) * | 1991-03-07 | 1996-10-10 | Virogenetics Corporation | Immunodeficiency virus recombinant poxvirus vaccine |
| AU674491B2 (en) * | 1991-03-20 | 1997-01-02 | Virogenetics Corporation | Recombinant poxvirus malaria vaccine |
| AU684070B2 (en) * | 1993-01-21 | 1997-12-04 | Virogenetics Corporation | Recombinant virus immunotherapy |
| AU721567B2 (en) * | 1995-06-06 | 2000-07-06 | Virogenetics Corporation | Recombinant poxvirus-calicivirus {rabbit hemorrhagic disease virus (RHDV)} compositions and uses |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
| US6248333B1 (en) | 1990-04-04 | 2001-06-19 | Health Research Inc. | Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD) |
| US5756102A (en) * | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| CN1089370C (zh) * | 1994-12-08 | 2002-08-21 | 中国预防医学科学研究院病毒学研究所 | 表达麻疹病毒l4株血凝素及融合蛋白基因的重组痘苗病毒 |
| AU2118997A (en) * | 1996-02-05 | 1997-08-22 | Johns Hopkins University, The | Measles immunization by dna transcription unit inoculation |
| AU750322B2 (en) | 1997-05-09 | 2002-07-18 | Trustees Of The University Of Pennsylvania, The | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| EP1095948A1 (en) * | 1999-10-28 | 2001-05-02 | Universitätsklinikum Freiburg | Idiotype vaccines |
| AU2002252199B2 (en) * | 2001-03-08 | 2008-01-03 | Emory University | MVA expressing modified HIV envelope, GAG, and POL genes |
| AR052743A1 (es) * | 2006-04-11 | 2007-03-28 | Inst Nac De Tecnologia Agropec | Vector plasmidico de transferencia y virus canarypox recombinante |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2617715B1 (fr) * | 1987-07-07 | 1990-08-31 | Transgene Sa | Vecteur viral et adn recombinant codant pour une ou des proteines de surface (ha et/ou f) d'un morbillivirus, culture cellulaire infectee, proteines obtenues, vaccin et anticorps obtenus |
| DE10399031I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| FR2632863B2 (fr) * | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| JPH01218590A (ja) * | 1988-02-29 | 1989-08-31 | Toa Nenryo Kogyo Kk | 組換ワクチニアウイルスを用いたリンダペスト（牛疫）ウイルスワクチン |
-
1991
- 1991-11-13 IE IE396091A patent/IE68404B1/en not_active IP Right Cessation
- 1991-11-13 IE IE960091A patent/IE71643B1/en not_active IP Right Cessation
- 1991-11-19 FR FR9114256A patent/FR2669346B1/fr not_active Expired - Lifetime
- 1991-11-19 BE BE9101066A patent/BE1005908A5/fr not_active IP Right Cessation
- 1991-11-20 DE DE4192786T patent/DE4192786T1/de active Pending
- 1991-11-20 WO PCT/US1991/008703 patent/WO1992008789A1/en not_active Ceased
- 1991-11-20 IT ITMI913092A patent/IT1252687B/it active IP Right Grant
- 1991-11-20 NL NL9120026A patent/NL195058C/nl not_active IP Right Cessation
- 1991-11-20 JP JP50520492A patent/JP3617668B2/ja not_active Expired - Fee Related
- 1991-11-20 GB GB9309414A patent/GB2264949B/en not_active Expired - Lifetime
- 1991-11-20 GB GB9500214A patent/GB2283021B/en not_active Expired - Lifetime
- 1991-11-20 AU AU12538/92A patent/AU1253892A/en not_active Abandoned
- 1991-11-20 CH CH2364/92A patent/CH683921A5/fr not_active IP Right Cessation
- 1991-11-20 CA CA002096633A patent/CA2096633A1/en not_active Abandoned
- 1991-11-20 DE DE4192786A patent/DE4192786B4/de not_active Expired - Lifetime
-
2003
- 2003-07-15 NL NL9900036A patent/NL195095C/nl not_active IP Right Cessation
-
2004
- 2004-06-09 JP JP2004170929A patent/JP3824619B2/ja not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU672359B2 (en) * | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| AU672581B2 (en) * | 1991-03-07 | 1996-10-10 | Virogenetics Corporation | Immunodeficiency virus recombinant poxvirus vaccine |
| AU674491B2 (en) * | 1991-03-20 | 1997-01-02 | Virogenetics Corporation | Recombinant poxvirus malaria vaccine |
| AU684070B2 (en) * | 1993-01-21 | 1997-12-04 | Virogenetics Corporation | Recombinant virus immunotherapy |
| AU721567B2 (en) * | 1995-06-06 | 2000-07-06 | Virogenetics Corporation | Recombinant poxvirus-calicivirus {rabbit hemorrhagic disease virus (RHDV)} compositions and uses |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2283021B (en) | 1995-07-05 |
| JP3617668B2 (ja) | 2005-02-09 |
| ITMI913092A0 (it) | 1991-11-20 |
| DE4192786T1 (de) | 1994-01-13 |
| IT1252687B (it) | 1995-06-23 |
| NL9120026A (nl) | 1993-09-01 |
| NL195095C (nl) | 2004-01-21 |
| CA2096633A1 (en) | 1992-05-21 |
| JP3824619B2 (ja) | 2006-09-20 |
| IE68404B1 (en) | 1996-06-12 |
| NL195058C (nl) | 2003-07-01 |
| ITMI913092A1 (it) | 1993-05-20 |
| JPH06502996A (ja) | 1994-04-07 |
| IE71643B1 (en) | 1997-02-26 |
| GB2264949A (en) | 1993-09-15 |
| BE1005908A5 (fr) | 1994-03-08 |
| CH683921A5 (fr) | 1994-06-15 |
| NL9900036A (nl) | 2003-10-01 |
| FR2669346B1 (fr) | 1995-07-21 |
| GB2264949B (en) | 1995-07-05 |
| DE4192786B4 (de) | 2006-08-24 |
| FR2669346A1 (fr) | 1992-05-22 |
| GB2283021A (en) | 1995-04-26 |
| GB9500214D0 (en) | 1995-03-01 |
| JP2005040129A (ja) | 2005-02-17 |
| GB9309414D0 (en) | 1993-07-14 |
| WO1992008789A1 (en) | 1992-05-29 |
| IE913960A1 (en) | 1992-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5364773A (en) | Genetically engineered vaccine strain | |
| KR970011149B1 (ko) | 재조합 아비폭스 바이러스 | |
| JP4108742B2 (ja) | ポックスウイルス−イヌジステンパーウイルス（ｃｄｖ）組み換え体類および組成物類および前記組み換え体類を用いる方法 | |
| US7144578B2 (en) | Poxvirus-rabies recombinants and compositions and methods employing the recombinants | |
| Taylor et al. | Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins | |
| US5843456A (en) | Alvac poxvirus-rabies compositions and combination compositions and uses | |
| CA1341234C (en) | Recombinant fowlpox virus | |
| NL195058C (nl) | Recombinant vacciniavirus en vaccin dat dit recombinant vacciniavirus bevat. | |
| AU724172B2 (en) | Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them | |
| US5989561A (en) | Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses | |
| US5503834A (en) | Measles virus recombinant poxvirus vaccine | |
| WO1996039177A9 (en) | Recombinant poxvirus-calicivirus [rabbit hemorrhagic disease virus (rhdv)] compositions and uses | |
| US5759841A (en) | Immunological composition of measles virus utilizing recombinant poxvirus | |
| EP0623172B1 (en) | Marek's disease virus recombinant vaccinia virus vaccine | |
| AU699903B2 (en) | Measles virus recombinant poxvirus vaccine | |
| AU720448B2 (en) | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants | |
| CA2187207C (en) | Poxvirus-canine distemper virus (cdv) recombinants and compositions and methods employing the recombinants | |
| AU769221B2 (en) | Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them | |
| Hu | Development of raccoon poxvirus-vectored feline recombinant vaccines |